Issue 94, 2014

Drug-like chelating agents: a potential lead for Alzheimer's disease

Abstract

Recent evidence has indicated that dyshomeostasis of biometals (Fe, Cu, Zn) in the brain might contributes to the pathogenesis of Alzheimer's disease (AD). Experiments have also found that the level of metal ions in AD patients was 3–7 fold higher than that of healthy individuals. Many drug-like chelating agents were found to be able to reverse Aβ aggregation, dissolve amyloid plaques and delay the AD-related cognitive impairment. This review systematically discusses the drug-like chelating agents for AD as well as their potential applications in the future.

Graphical abstract: Drug-like chelating agents: a potential lead for Alzheimer's disease

Article information

Article type
Review Article
Submitted
25 août 2014
Accepted
09 oct. 2014
First published
09 oct. 2014

RSC Adv., 2014,4, 52088-52099

Drug-like chelating agents: a potential lead for Alzheimer's disease

W. Huang, W. Wei and Z. Shen, RSC Adv., 2014, 4, 52088 DOI: 10.1039/C4RA09193K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements